The COX-2 story: is any drug completely "safe?".
作者信息
DuBois Raymond N
出版信息
Gastroenterology. 2006 Jan;130(1):6. doi: 10.1053/j.gastro.2005.11.045.
PMID:16401461
Abstract
摘要
相似文献
1
The COX-2 story: is any drug completely "safe?".环氧化酶-2的故事：有哪种药物是完全“安全”的？
Gastroenterology. 2006 Jan;130(1):6. doi: 10.1053/j.gastro.2005.11.045.
2
Risks and benefits of celecoxib to prevent recurrent adenomas.塞来昔布预防复发性腺瘤的风险与获益
N Engl J Med. 2006 Aug 31;355(9):950-2. doi: 10.1056/NEJMe068158.
3
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?罗非昔布使腺瘤缩小的证明是得不偿失的胜利吗？
Gastroenterology. 2006 Dec;131(6):2003-5. doi: 10.1053/j.gastro.2006.10.052.
4
The COX-2 inhibitors--an update.环氧化酶-2抑制剂——最新进展
Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022.
5
Clinical inquiries. Do COX-2 inhibitors worsen renal function?临床咨询。环氧化酶-2抑制剂会使肾功能恶化吗？
J Fam Pract. 2007 Nov;56(11):957-8.
6
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?环氧化酶-2 选择性抑制剂与前列腺癌：临床益处何在？
J Clin Oncol. 2006 Jun 20;24(18):2691-3. doi: 10.1200/JCO.2006.05.9709.
7
Clinical Questions #6. Does celecoxib increase cardiovascular risk?临床问题#6. 塞来昔布是否会增加心血管风险？
WMJ. 2005 Nov;104(8):15-6.
8
Chemopreventive effect of celecoxib in gastric cancer.塞来昔布在胃癌中的化学预防作用。
Inflammopharmacology. 2007 Feb;15(1):1-4. doi: 10.1007/s10787-006-1541-5.
9
Decisions that put patients at risk.将患者置于风险中的决定。
Prescrire Int. 2011 Mar;20(114):60.
10
Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.炎症性肠病中选择性非甾体抗炎药的选择性使用
Clin Gastroenterol Hepatol. 2006 Feb;4(2):157-9. doi: 10.1016/j.cgh.2005.11.007.
Zotero 插件